Original article: High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: A model of care in Khayelitsha, South Africa

Southern African Journal of HIV Medicine

Volumn 14, Issue 4, 2013, Pages 166-169

  Garone, D B ^a   Conradie, K ^a   Patten, G ^a   Cornell, M ^b   Goemaere, E ^a,b   Kunene, J ^c   Kerschberger, B ^a   Ford, N ^a,b,c   Boulle, A ^b   Van Cutsem, G ^a,b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Department of Biomedical Sciences   (South Africa)

^c Ubuntu Clinic   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COUNSELING; SOUTH AFRICA; TREATMENT DURATION; VIRUS LOAD;

EID: 84892422768     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.7196/SAJHIVMED.980     Document Type: Article

References (22)

1. Joint United Nations Programme on HIV/AIDS. Global update on HIV treatment 2013: Results, Impact and Opportunities. Geneva: UNAIDS, 2013
2. Johnson L. Access to antiretroviral treatment in South Africa, 2004 -2011. Southern African Journal of HIV Medicine 2012;13(1):22-27.
3. Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy: Township South Africa and Switzerland compared. PLoS Med 2008;5(7):e148. [http://dx.doi.org/10.1371/journal.pmed. 0050148]
4. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study. Lancet Infect Dis 2011;11(10):750-759. [http://dx.doi.org/10.1016/S1473-3099(11)70149-9]
5. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010;24(6):915-919. [http://dx.doi.org/10.1097/QAD.0b013e3283360976]
6. Boyd MS, Emery S, Cooper DA. Antiretroviral roll-out: The problem of second-line therapy. Lancet 2009;374(9685):185-186. [http://dx.doi.org/10.1016/ S0140-6736(09)61313-1]
7. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: A cross-sectional study in Soweto, South Africa. AIDS 2010;24:1679-1687. [http://dx.doi.org/10.1097/QAD. 0b013e32833a097b]
8. Boulle A, van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010;24(4):563-572. [http://dx.doi.org/10.1097/QAD.0b013e328333bfb7]
9. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. http://aidsinfo.nih. gov/contentfiles/AdultandAdolescentGL003093.pdf (accessed 1 August 2013).
10. National Department of Health. The South African Antiretroviral Treatment Guidelines, Pretoria: NDoH 2013
11. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011;56(4):333-339. [http://dx.doi.org/10.1097/QAI.0b013e31820dc0cc]
12. Médecins Sans Frontières. Khayelitsha 2001 -2011. Activity Teport: 10 years of HIV/TB Care at Primary Health Care Level. Cape Town: MSF, 2012.
13. Renaud-Théry F. Adult antiretroviral therapy in resource limited settings: A systematic review of first-line failure and attrition rates. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
14. Ajose O, Mookerjee S, Mills EJ, et al. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: A systematic review and meta-Analysis. AIDS 2012;26(8):929-938. [http://dx.doi.org/0.1097/ QAD.0b013e328351f5b2]
15. Conradie K, Cox V, Wilkinson L. Supporting adherence to antiretroviral treatment: A facility approach to reduce the risk of treatment failure. Nursing Matters 2013;4(3):20-23.
16. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146(8):564-573. (Pubitemid 351650537)
17. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133(1):21-30. (Pubitemid 30432540)
18. Shuter J, Sarlo JA, Kanmaz TJ, et al. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45(1):4-8. (Pubitemid 46684437)
19. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010;55(4):460-465. [http://dx.doi.org/10.1097/QAI.0b013e3181f2ac87]
20. Coetzee D, Boulle A, Hildebrand K, et al. Promoting adherence to antiretroviral therapy: The experience from a primary care setting in Khayelitsha, South Africa. AIDS 2004;18(Suppl 3):S27-S31. (Pubitemid 39037456)
21. Wallis CL, Mellors JW, Venter WD, et al. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat 2011;2011:769627. [http://dx.doi.org/10.1155/2011/769627]
22. Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 2012;7(3):e32144. [http://dx.doi.org/10.1371/journal.pone.0032144]